Company Overview
| Stock Name | Ascletis-B |
|---|---|
| Stock Code | 01672 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 歌禮是一個一體化抗病毒平台,專注於開發及商業化針對丙肝、HIV和乙肝的創新的、同類最佳的藥物,涵蓋從發現和開發到生產和商業化的整個價值鏈。 |
| Listing Date | 2018-08-01 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省杭州市濱江區江漢路1785號雙城國際4幢18層 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東28號金鐘匯中心18樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.ascletis.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 14.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2018-07-20 to 2018-07-25 |
| Global Offering Shares | 224,137,000 shares |
| HK Public Offer Shares (Initial) | 22,414,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 201,723,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,120,685,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 18.8% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 3,137,918,000 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 11.36B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 2017年虧損人民幣86.9百萬元 |
| Period-End Cash Balance | 人民幣607.4百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | 1.55億美元 |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 | 2017 | 2018-03 |
|---|---|---|---|
| Revenue | 32,976 | 53,202 | 51,062 |
| Gross profit | 32,976 | 53,202 | 51,062 |
| Other income and gains, net | 14,496 | 49,593 | 6,437 |
| Administrative expenses | -15,044 | -37,477 | -15,717 |
| Profit before tax | -31,873 | -80,441 | -983 |
| Income tax expense | -6,490 | 125 | |
| Profit for the year | -31,873 | -86,931 | -858 |
| Profit attributable to owners | -26,807 | -53,935 | 11,629 |
Balance Sheet
| Item | 2016 | 2017 | 2018-03 |
|---|---|---|---|
| Cash and cash equivalents | 418,973 | 607,367 | 526,022 |
| Inventories | 18,747 | 62,211 | 69,188 |
| Total current assets | 466,008 | 875,618 | 773,636 |
| Total current liabilities | 73,399 | 99,228 | 67,899 |
| Total equity | 409,084 | 869,831 | 799,937 |
| Equity attributable to owners | 272,359 | 596,961 | 597,341 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018-03 |
|---|---|---|---|
| Net cash from operating activities | -12,498 | -198,056 | -45,741 |
| Net cash from investing activities | -37,633 | -644,542 | 170,526 |
| Net cash from financing activities | 88,159 | 549,362 | -57,815 |
| Net increase in cash | 38,028 | -293,236 | 66,970 |
| Depreciation of PP&E | 579 | 2,108 | 586 |
| Amortisation of intangible assets | 1,892 | 3,442 | 978 |
| Purchase of PP&E | -44,606 | -15,298 | -2,854 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 14.0 |
|---|---|
| First Day Open | HK$ 14.8 |
| First Day Change | 19.57% |
| First Day Volume | 82741300.0 |
| First Day Turnover | 1179890000.0 |
| Use of Proceeds | 1、約30.0%或892.8百萬港元將用于我們核心產品線的持續研發;
2、約25.0%或744.0百萬港元將用于戈諾衛及拉維達韋商業化;
3、約15.0%或446.4百萬港元將用于尋求新在研藥物的引進許可,盡管我們截至最后實際可行日期尚未物色到任何潛在目標;
4、約10.0%或297.6百萬港元將用于通過啟動及進行臨床試驗進行ASC21的研發;
5、約10.0%或297.6百萬港元將用于支持我們的研發基礎設施及HBV及NASH發現階段兩個內部藥物計劃的早期開發;
6、約10%或297.6百萬港元將用于我們的營運資金及作其他一般公司用途。 |
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (3)
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | GIC Private Limited | 588,588,000 HKD | — | 18.76% | — | 6 months | 2019-02-01 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 吳勁梓 | — |
| Company Secretary | 王漸炯、嚴洛鈞 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 吳博士及吳夫人合共持有約53.29%股權;JJW11 Limited持有5.80%;CBC Investment Twelve Limited持有5.93%;CBC Investment Fifteen Limited持有6.45%。 |
|---|




